...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Response - leaves us guessing:(

This is what irritates/PM off, you & the market obviously. "Selective Disclosure" Don't be "selective" then - tell everyone just what the frick the details are - will this mushroom type crap ever end!!!


"Hi xxx


Thank you for your questions. I can appreciate that you would like additional information on the announced agreement with Cencora. However, to avoid selective disclosure I am unable to share details with you at this time, beyond what was included in last week's press release and discussed at the AGM.

Thank you for your patience and understanding.

Best regards,

Chris"

Share
New Message
Please login to post a reply